BioBoss is a podcast about leadership in the biopharma community. Hear directly from the founders and CEOs of today's most innovative companies. Listen each month as Wyant Simboli Principal and branding veteran John Simboli poses the questions "What drives you? How do you make change? Why should I care?" to a new biopharma executive and hear insights on this rapidly changing field.
#28 - Mark Altmeyer: Founder and CEO of Arvelle Therapeutics
Mark Altmeyer, founder and CEO of Arvelle Therapeutics, speaks with BioBoss host John Simboli. Hear Mark’s thoughts about leadership and how Arvelle is working to bring new solutions to people living with epilepsy and CNS disorders.
#27 - Jacob Becraft: Co-Founder & CEO, Strand Therapeutics
Jacob Becraft, co-founder & CEO of Strand Therapeutics shares his thoughts with BioBoss host John Simboli about leadership and how Strand is working in synthetic biology and messenger RNA to target root causes of genetic disease, with the power to control editing at a single-cell level.
#26 - Eran Eden: Co-Founder and CEO of MeMed
Eran Eden, co-founder and CEO of MeMed, shares his thoughts on leadership and how MeMed is working to translate signals from the immune system into diagnostic insights to treat infectious disease and inflammatory disorders.
#25 - Nikolaj Sørensen: CEO of Orexo
Nikolaj Sørensen, CEO of Orexo Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership and, digital and bio-therapeutics, how the coronavirus is changing the landscape around mental health, depression, substance abuse and addiction,
#24 - Per Hellsund: Co-Founder and CEO of Cybrexa
Per Hellsund, co-founder and CEO of Cybrexa Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership, building a culture of transparency, and Cybrexa's advances in treating the cancer tumor microenvironment.
#23 - Clive Morris: CEO of Inivata
CEO Clive Morris of Inivata, headquartered in Cambridge U.K., shares his thoughts with BioBoss host John Simboli about leadership in biotech and advances in non-invasive liquid biopsy to unlock genomic information and guide personalized cancer treatment.